Incruse Ellipta (umeclidinium) inhalation powder

Incruse Ellipta is a pharmaceutical product used for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). It contains the active ingredient umeclidinium, which is a long-acting muscarinic antagonist (LAMA).

The brand was developed and is owned by GlaxoSmithKline (GSK), a major British multinational pharmaceutical company. The Ellipta inhaler device itself was also developed by GSK to deliver a range of respiratory medicines. Manufacturing for these inhalers primarily takes place in the United Kingdom, specifically at GSK's specialized respiratory manufacturing facilities in Ware, Hertfordshire.

GSK remains the ultimate owner and marketer of the product globally. In many regions, including the Nordic market, the product is distributed through GSK's local subsidiaries, ensuring that quality and safety standards are maintained across all territories.